CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy

被引：0
|
作者：
Laura E. Jansen
Wendy A. Teft
Rhiannon V. Rose
Daniel J. Lizotte
Richard B. Kim
机构：
[1] Western University,Department of Medicine, Division of Clinical Pharmacology
[2] Western University,Department of Epidemiology and Biostatistics
[3] Western University,Department of Oncology
[4] LHSC-University Hospital,Department of Medicine
来源：
Breast Cancer Research and Treatment | 2018年 / 171卷
关键词：
Breast cancer; Tamoxifen; Endoxifen; Hot flash; Pharmacogenomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：701 / 708
页数：7
相关论文
共 50 条
  • [1] CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
    Jansen, Laura E.
    Teft, Wendy A.
    Rose, Rhiannon V.
    Lizotte, Daniel J.
    Kim, Richard B.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 701 - 708
  • [2] CYP2D6 and CYP3A influence tamoxifen and endoxifen
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 524 - 525
  • [3] CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart
    Skaar, Todd C.
    Desta, Zeruesenay
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 755 - 757
  • [4] CYP2D6 genotype and tamoxifen response
    James M Rae
    Matthew P Goetz
    Daniel F Hayes
    James N Ingle
    Lang Li
    Anna Maria Storniolo
    Vered Stearns
    David A Flockhart
    Breast Cancer Research, 7
  • [5] CYP2D6 Genotype and Adjuvant Tamoxifen
    Berry, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 138 - 140
  • [6] CYP2D6 genotype and tamoxifen response
    Rae, JM
    Goetz, MP
    Hayes, DF
    Ingle, JN
    Li, L
    Storniolo, AM
    Stearns, V
    Flockhart, DA
    BREAST CANCER RESEARCH, 2005, 7 (05)
  • [7] CYP2D6 genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.
    Balakrishnar, Bavanthi
    Menzies, Alexander M.
    Ali, Sayed Sahanawaz
    Yeap, Shang Heng
    Gao, Bo
    Liddle, Chris
    Coulter, Sally
    Provan, Pamela
    Gebski, Val
    Hui, Rina
    Kefford, Richard
    Wilcken, Nicholas
    Balleine, Rosemary L.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [9] Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy
    Schultink, Aurelia H. M. de Vries
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    BREAST, 2018, 42 : 38 - 40
  • [10] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
12345